HANNOVER
16.11.2015 17:31:45 CET | Business Wire | Press release
Cvent compiled this first annual list on the basis of data evaluation from conference planners and their levels of interaction with over 2,500 European hotels and locations. Data from July 2014 to June 2015 was taken into consideration. Hannover won points as a city in the heart of Europe with the largest exhibition grounds in the world and an exceptional and multi-faceted location.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151116006084/en/
Cvent is a leading cloud-based event management platform for companies. They offer software solutions for location selection, mobile apps for events, Web surveys as well as providing hotels with a platform for targeted advertising campaigns. The platform, which started in the USA, operates internationally and has a website and contact persons in Germany.
“We are in very good company in this ranking list and quite rightly so. Not only a modern infrastructure, central position, the largest exhibition grounds in the world and unique locations have helped the Hannover region to establish itself as a strong centre in the heart of Europe for events of all kinds,” commented Hans Christian Nolte, managing director of Hannover Marketing und Tourismus GmbH.
Hannover at the IBTM in Barcelona
International representation: HannoverKongress, the Deutsche Messe AG and the Hannover Congress Centrum (HCC) are exhibiting from 17 to 19 November under the motto “The Meeting Planet – Wide awake: day + night”.
Alongside IMEX, ibtm world held in Barcelona, is one of the most important trade fairs for the conference, incentive and business travel industry. Nearly 5,000 exhibitors from over 100 countries exhibit every year for around 15,500 trade visitors from the congress and incentive industry. The goals are simple – to provide the best B2B platform, supported by an excellent network and an extensive, global hosted buyer programme.
HannoverKongress
HannoverKongress is the partner for congresses and conferences in the Hannover region. The congress service of Hannover Marketing und Tourismus GmbH, helps customers to organise successful events with tailor-made solutions free of commission.
More information can found here: www.hannoverkongress.de/english and www.visit-hannover.com/en .
Visit Hannover – Trade Fairs 2016
CeBIT
2016
– Partner Country Switzerland: 14-18 March 2016
Hannover
Messe
– Partner Country USA: 25-29 April 2016
View source version on businesswire.com: http://www.businesswire.com/news/home/20151116006084/en/
Contact:
Hannover Marketing und Tourismus GmbH
Laura Harke, +49 511
12345-444 | Fax: +49 511 12345-445
info@hannoverkongress.de
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom